A Gene Editing Breakthrough
By Tom Ashbrook,
NPR On Point [features Marcy Darnovsky]
| 08. 08. 2017
After the blockbuster announcement a U.S. team successfully edited human embryos come the tough medical and ethical questions. We’ll talk it through.
A first in the U.S.: researchers have now edited the genetic code of viable human embryos, cutting and splicing to avoid defect and disease. The DNA of human embryos. Genetically edited. The edited embryos weren’t implanted in a woman. Weren’t born. But they could have been. New life spared disease, maybe death. How far does this gene editing go? How fast? For whom? And for, or against, what human traits? This hour On Point: editing the code of human life. -- Tom Ashbrook
Guests
Amy Dockser Marcus, health and science reporter for the Wall Street Journal. (@AmyDMarcus)
Dr. Paula Amato, co-author of the study showing successful editing of genes in human embryos. Associate professor of obstetrics and gynecology at Oregon Health & Science University.
Arthur Caplan, professor of bioethics and head of the division of medical ethics at the New York University School of Medicine. (@ArthurCaplan)
Marcy Darnovsky, executive director of...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...